Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Early Moderate to Severe Rheumatoid Arthritis
NCT01251120Phase 4Terminated
- Sponsor
- Roche
- Start
- Nov 2011
- Primary completion
- Jan 2013
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Achieving Disease Remission Assessed Using the Disease Activity Score Based on 28-Joint Count (DAS28) at 12 months. Started Nov 2011; status: terminated.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01251120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251120.